0.8151
price up icon2.46%   0.0196
after-market After Hours: .83 0.0149 +1.83%
loading
Cue Biopharma Inc stock is traded at $0.8151, with a volume of 172.77K. It is up +2.46% in the last 24 hours and up +9.93% over the past month. Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.7955
Open:
$0.84
24h Volume:
172.77K
Relative Volume:
0.61
Market Cap:
$62.64M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.8957
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
+12.04%
1M Performance:
+9.93%
6M Performance:
+6.40%
1Y Performance:
-33.73%
1-Day Range:
Value
$0.801
$0.8568
1-Week Range:
Value
$0.713
$0.96
52-Week Range:
Value
$0.5406
$1.9891

Cue Biopharma Inc Stock (CUE) Company Profile

Name
Name
Cue Biopharma Inc
Name
Phone
617-949-2680
Name
Address
40 GUEST STREET, BOSTON, MA
Name
Employee
41
Name
Twitter
@cuebiopharma
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
CUE's Discussions on Twitter

Compare CUE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CUE
Cue Biopharma Inc
0.8151 61.13M 9.53M -44.61M -38.32M -0.91
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-24 Initiated Jefferies Buy
Jun-26-23 Resumed Oppenheimer Outperform
Nov-21-22 Initiated Piper Sandler Overweight
Jan-13-22 Initiated H.C. Wainwright Buy
Jan-03-22 Initiated Craig Hallum Buy
Nov-24-20 Initiated Berenberg Buy
Apr-09-20 Initiated Stifel Buy
Jan-28-20 Initiated BTIG Research Buy
Jan-22-20 Initiated JMP Securities Mkt Outperform
View All

Cue Biopharma Inc Stock (CUE) Latest News

pulisher
10:12 AM

What dividend safety score for Cue Biopharma Inc. stockRecession Risk & Long-Term Safe Investment Plans - newser.com

10:12 AM
pulisher
09:58 AM

Is Cue Biopharma Inc. (1UC) stock undervalued after correctionTrade Signal Summary & Free Real-Time Market Sentiment Alerts - newser.com

09:58 AM
pulisher
09:11 AM

What recovery options are there for Cue Biopharma Inc.Buy Signal & Momentum Based Trading Ideas - newser.com

09:11 AM
pulisher
Oct 12, 2025

Is Cue Biopharma Inc. stock a top momentum play2025 Technical Overview & Risk Controlled Swing Trade Alerts - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Published on: 2025-10-12 06:58:11 - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

What drives Cue Biopharma Inc stock priceValue Stock Picks & Low Cost Trading Ideas - earlytimes.in

Oct 12, 2025
pulisher
Oct 10, 2025

Will Cue Biopharma Inc. stock recover after recent dropJuly 2025 Momentum & Verified Momentum Watchlists - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Using portfolio simulators with Cue Biopharma Inc. includedLayoff News & Community Consensus Stock Picks - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

How Cue Biopharma Inc. (1UC) stock stacks up against competitorsJuly 2025 Pullbacks & Weekly High Potential Stock Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Cue Biopharma stock adds to gains after Nobel Prize validates CUE-401 approach - Investing.com Nigeria

Oct 09, 2025
pulisher
Oct 09, 2025

Is Cue Biopharma (NASDAQ:CUE) Using Debt In A Risky Way? - simplywall.st

Oct 09, 2025
pulisher
Oct 09, 2025

Tick level data insight on Cue Biopharma Inc. volatility2025 Growth vs Value & Reliable Breakout Forecasts - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is it time to cut losses on Cue Biopharma Inc.Trade Risk Assessment & Daily Chart Pattern Signals - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

Cue Biopharma, Inc. (NASDAQ:CUE) Sees Significant Drop in Short Interest - MarketBeat

Oct 07, 2025
pulisher
Oct 06, 2025

Will Cue Biopharma Inc. stock reach all time highs in 2025July 2025 Intraday Action & Safe Entry Point Alerts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Reversal indicators forming on Cue Biopharma Inc. stockAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Will breakout in Cue Biopharma Inc. lead to full recoveryVolume Spike & Daily Growth Stock Tips - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Developing predictive dashboards with Cue Biopharma Inc. dataMarket Sentiment Report & Free Growth Oriented Trading Recommendations - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Market reaction to Cue Biopharma Inc.’s recent news2025 Top Decliners & Daily Profit Focused Screening - newser.com

Oct 02, 2025
pulisher
Sep 30, 2025

Cue Biopharma names Usman Azam as new CEO and president - The Pharma Letter

Sep 30, 2025
pulisher
Sep 30, 2025

Building trade automation scripts for Cue Biopharma Inc.2025 Bull vs Bear & Consistent Income Trade Recommendations - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Cue Biopharma names Usman Azam as new CEO, shifts focus to autoimmune disease - Investing.com Nigeria

Sep 30, 2025
pulisher
Sep 29, 2025

Cue Biopharma Appoints Usman “Oz” Azam, M.D., as CEO - citybiz

Sep 29, 2025
pulisher
Sep 29, 2025

Cue Biopharma Appoints Usman Azam as New CEO - TipRanks

Sep 29, 2025
pulisher
Sep 29, 2025

Cue Biopharma, Inc. Appoints Usman ?Oz? Azam, M.D. as President, Effective September 29, 2025 - MarketScreener

Sep 29, 2025

Cue Biopharma Inc Stock (CUE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):